Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research ...

Lehigh Valley’s health networks are seeing abnormally high cases of the stomach bug that’s taking a large number of people ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

The New York Times reports that the tentative $7.4 billion agreement with 15 states would also require those states to set aside as much as $800 million in what amounts to a legal defense fund for the ...

The S&P 500 notched a fresh record on Thursday. The broad market index gained 0.5% for its fourth positive session in a row ...

A surge in respiratory illness is typical for this time of year, and the simultaneous outbreak of highly contagious norovirus is piling on to the public health risk. Commonly known as stomach flu, ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

While norovirus is not generally life-threatening, the CDC reports that it causes 900 deaths and 109,000 hospitalizations on ...